title: Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
abstract: BACKGROUND
  Compared with systemic therapy, hepatic arterial infusion (HAI) increases the response to fluoropyrimidines.
  
  
  METHODS
  Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest.
  
  
  RESULTS
  The objective response rate was 65% (all 20 patients achieving a partial response). Ten patients (32%) had stable disease. The median time to progression (TTP) and overall survival (OS) were 12 and 36 months. OS was similar in patients with low versus high expression of thymidylate synthase (TS) and/or dihydropyrimidine dehydrogenase (DPD). The regimen was well tolerated.
  
  
  CONCLUSIONS
  UFT with LV plus HAI irinotecan and 5-FU/LV was a feasible and effective treatment for non-resectable CRC liver metastases, increasing response, TTP and OS. TS and DPD levels in liver metastases did not predict outcome.
authors.affiliation: Institute of Oncology, Kaplan Medical Center, Rehovot, Israel. efraim_i@clalit.org.il
authors.forename: Efraim
authors.initials: E
authors.lastname: Idelevich
authors.forename: Franklin
authors.initials: F
authors.lastname: Greif
authors.forename: Eli
authors.initials: E
authors.lastname: Mavor
authors.forename: Rafael
authors.initials: R
authors.lastname: Miller
authors.forename: Hanoch
authors.initials: H
authors.lastname: Kashtan
authors.forename: Sergo
authors.initials: S
authors.lastname: Susmalian
authors.forename: Arie
authors.initials: A
authors.lastname: Ariche
authors.forename: Baruch
authors.initials: B
authors.lastname: Brenner
authors.forename: Noa Ben
authors.initials: NB
authors.lastname: Baruch
authors.forename: Michael
authors.initials: M
authors.lastname: Dinerman
authors.forename: Adi
authors.initials: A
authors.lastname: Shani
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000473:pathology*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000032:analysis; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D042943:Dihydrouracil Dehydrogenase (NADP); D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin